Individual safety findings for one molecule dont necessarily predict class-wide effects, says Finer, safety signals often relate to specific structural features or off-target activities rather than the primary mechanism of action. He thinks oral GLP-1 drugs have the potential for better dose titration, which might help control the current, mainly gastrointestinal, side-effects of the injectable peptides
Every day you wait, dark spots deepen, fine lines multiply, and you're wasting money on products delivering half the results
Fabregat, A
Future of GLP-1 receptor agonists In a related editorial, Thiara noted that although Tang and colleagues found that GLP-1 receptor agonists and SGLT2 inhibitors had a similar effect on ADRD, the team did show that isolating semaglutide, the newest and most potent GLP-1 receptor agonist on the market, showed decreased risk of ADRD compared with SGLT2 inhibitors. Both studies had limitations, including short-term follow-up, low dementia event rates and confounding variables, Thiara wrote